Cerebramin
Brain cytamin — Khavinson-school organ peptide fraction, oral tablet
Cerebramin (Brain cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A Khavinson-school polypeptide fraction extracted from animal brain and pressed into a 155mg tablet — the older CYTAMIN line, not the synthetic cytogens or the cytomax capsules the Vault already covers. The class claim is tissue-specific regulation of gene expression in the organ the extract came from. The only member of this family whose pharmacology has actually been measured is the injectable brain preparation Cortexin, which reached mouse brain at 6-8% of whole-blood concentration and screened as a glutamatergic agent — 80.1% binding at AMPA and 73.5% at kainate receptors — rather than as the DNA-binding regulator the class is sold as.
Cerebramin quick facts
| Route | Oral |
| Frequency | Not established · Not established |
| Half-life | Not characterized — no analytical method for this preparation has been published |
| Forms | Oral |
| Evidence level | No published study of this product. The literature belongs to the parenteral extracts and the synthetic peptides of the same school. |
MoCA and trail making are free, take fifteen minutes, and are the instruments that would detect what this tablet is bought for. Nobody has run either on it: a PubMed search for the product's name on 8 September 2026 returned zero records. The measured brain-penetration figure in this family belongs to an injectable, and an oral extract has to cross the gut wall before it meets that barrier at all.
How Cerebramin works
A Khavinson-school polypeptide fraction extracted from animal brain and pressed into a 155mg tablet — the older CYTAMIN line, not the synthetic cytogens or the cytomax capsules the Vault already covers. The class claim is tissue-specific regulation of gene expression in the organ the extract came from. The only member of this family whose pharmacology has actually been measured is the injectable brain preparation Cortexin, which reached mouse brain at 6-8% of whole-blood concentration and screened as a glutamatergic agent — 80.1% binding at AMPA and 73.5% at kainate receptors — rather than as the DNA-binding regulator the class is sold as.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Cerebramin
Buy Cerebramin at RUPharma →The evidence for Cerebramin
Graded by what exists behind each claim.
✅ Clinically validated
- None. A PubMed search through PubTator3 for this product's name, run 8 September 2026, returned zero records. No trial, no case series, no pharmacokinetic study.
📊 Correlative data
- The measured pharmacology in this family belongs to Cortexin, the injectable brain polypeptide: radiolabeled, it reached mouse brain at 6-8% of whole-blood concentration, and a receptor screen found 80.1% binding at AMPA and 73.5% at kainate receptors (Kurkin 2021). Different product, parenteral route.
- Cortexin at 2-40 micrograms/ml protected cultured rat sensory neurons against 50 mM glucose, restoring a cell-index area-under-curve from 0.18 to 0.66 (Yazar 2023). Cells in a dish, material applied directly.
🧪 Theoretical / extrapolated
- The class claim is tissue-specific regulation of gene expression by short peptides released from an organ fraction. The receptor panel above points a different way — at fast excitatory transmission — and it is the manufacturer's own network that produced it.
- Two barriers in series. A brain product has to survive digestion, cross the gut, and then cross a blood-brain barrier that the injectable work already found lets through under a tenth of what is in blood. Neither step has been measured for a tablet.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Cerebramin actually does
There is exactly one brain preparation in this whole catalog whose pharmacology somebody actually measured, and it is not this one. Kurkin 2021 took Cortexin — the injectable bovine cortex polypeptide complex — labeled it radioactively, and found it in mouse brain at 6 to 8% of the whole-blood concentration. That single number is the only measured tissue penetration figure anywhere in the Khavinson family, and it was obtained after an injection.
The same paper screened it against a receptor panel, and the answer was not the one the marketing predicts. High binding at AMPA (80.1%) and kainate (73.5%) receptors, moderate at mGluR1 (49.0%), GABA-A1 (44.0%) and mGluR5 (39.7%) Kurkin 2021. That is a glutamatergic profile. It is the profile of a drug acting on fast excitatory transmission, not of a gene-regulatory agent binding DNA, which is the story the class is sold on Khavinson 2021. The manufacturer's own research network produced that result.
What the tablet in front of you is, stated without decoration. A 155 mg pressed tablet of a nucleoprotein fraction extracted from animal brain, 40 to a pack, listed by a partner at $42. Nobody publishes a composition for it: no peptide profile, no molecular-weight distribution, no assay of any kind. So the mechanism section for this product has to be written the honest way — by describing what has been measured on its closest relatives and saying at every step which product that was and how it was administered.
The nearest thing to a cell-level result for a brain extract, with its concentration. Yazar 2023 applied Cortexin at 2 to 40 µg/ml directly to cultured rat dorsal-root-ganglion neurons under 50 mM glucose. High glucose collapsed the cell index area-under-curve from 1.00 ± 0.00 to 0.18 ± 0.02; co-treatment at 40 µg/ml brought it back to 0.66 ± 0.17 (P = 0.002). A real, concentration-dependent effect — on sensory neurons in a dish, bathed in the material at a fixed concentration, which is a very long way from a swallowed tablet.
Cell, rodent, human — and where it stops
Start with the search, because the search is the finding. A PubTator3 query of PubMed for the single word naming this product, run 8 September 2026, returned zero records. A query for the product class, cytamins, returned one Tokaev 2007 — a Russian nutrition review that lists the class among bioactive substances for liver disease. There is no trial of this tablet, no pharmacokinetic study of it, and no case series. Everything below is about something else, and the sentences say which.
Corrected 9 September 2026: the class word has a second spelling and it is the productive one. Querying cytamines rather than cytamins returns eleven records, four of them about this product line — two human reports Khavinson 2001 Emirova 2004, a manufacturing and screening paper Ryzhak 2003, and a follow-up from the same sports laboratory Rozhkova 2007. That is a larger class literature than this page first reported, and saying so comes before saying what it does not contain.
What it does not contain is the brain. The 2004 athletics paper states which cytamins were given — hepatamin, epifamin and suprenamin, the liver, pineal and adrenal tablets. The cerebral tablet is not among them. Khavinson 2001 is a 2001 note in a Russian military medical journal whose title states a purpose rather than a result, and PubTator3 returns its title, authors, journal and year with no abstract, so there is no design, no sample size and no endpoint to read out of it. Neither paper moves this tablet a rung up the chain.
The explant rung, and the tissue it used. Khavinson 2002 tested polypeptide preparations isolated from cerebral cortex (Cortexin), epiphysis, liver and thymus on explants of rat cerebral cortex and subcortical structures, in rats of different ages, and reported tissue-specific stimulation of explant growth. Ryzhak 2015 repeated the exercise with calf-tissue polypeptides at 0.01 to 100 ng/ml on matching organotypic cultures from young and old rats. Both are cell-culture experiments in which the material is pipetted onto the tissue.
The animal rung belongs to the injectable, and it is recent. Kurkin 2025 reports neurotropic effects of Cortexin in rodent models of mental and physical developmental delay; Kurkin 2021 compared it against Cerebrolysin and Actovegin in acute cerebral ischemia and is where the 6-8% brain-penetration figure and the receptor panel come from. Different product, parenteral route.
And here is the break in the chain, in one sentence. Every positive result above was produced either by putting the material directly onto neural tissue or by injecting it, and the step nobody has taken is the one this product requires: showing that anything measurable survives the stomach, crosses the intestinal wall, and then crosses a second barrier the injectable work already found to be 92-94% impermeable on its own terms. Two barriers in series, one of them quantified for the other product, neither of them measured for this one.
Cerebramin pharmacokinetics — how much of it actually gets in
What degrades it, and the first barrier is not the interesting one. A nucleoprotein complex is protein plus nucleic acid. Gastric acid denatures it, pepsin cleaves it, pancreatic proteases finish the job and brush-border peptidases hydrolyze what is left to free amino acids and di- and tripeptides. That is not a hypothesis about this product; it is what happens to dietary protein, and there is no published reason to think a pressed tablet of animal brain fraction is exempt. Enteric coating is not claimed by the vendor and no dissolution data exists.
The second barrier is the one that makes a brain product different from every other tablet on this shelf. Even granting that some fragment reaches the portal circulation intact, the blood-brain barrier is in the way — and for this family that barrier has actually been quantified. Radiolabeled Cortexin reached mouse brain at 6 to 8% of whole-blood concentration after parenteral administration Kurkin 2021. Read that as a ceiling, and note how it was obtained: after an injection, with 100% of the dose already in blood, under a tenth of it reached brain. An oral product starts that journey from behind the gut wall, and no injection of this tablet's material has ever been given to anything.
The arithmetic, done in both directions so it is not a rigged comparison. A 155 mg tablet distributed instantly and intact into 5 liters of blood would give about 31 µg/ml, which is comfortably inside the 2-40 µg/ml range that worked on cultured neurons Yazar 2023 and vastly above the 0.01-100 ng/ml used on explants Ryzhak 2015. So the dish concentrations are not out of reach in principle — even at 1% intact absorption the blood level would still sit in the explant range. That is the strongest honest argument this product has, and it collapses at the brain barrier rather than at the gut: 1% of 8% is 0.08%, and nobody has measured either figure for a tablet.
Half-life cannot be stated because nothing has been assayed. There is no analytical method published for this preparation, so there is no analyte to follow. What can be said is the shape: free amino acids and small peptides released from a protein meal clear over hours, and any pharmacology would therefore be a transient event tied to dosing rather than a steady state. The 40-tablet pack implies a 20-to-40-day course, which is a schedule, not a pharmacokinetic argument.
What would have to be true, and how you would know it was not
Four predictions. The first is the one a reader can run this month, and the second cuts against the product.
1. MoCA and trail making, before and after a full pack. Both are free, both take under fifteen minutes, both are the instruments used to detect exactly the change this product is bought for, and zero published studies of this tablet have administered either. Score at baseline, score again the day the 40-tablet pack runs out. A dozen people doing that would produce more human data on Cerebramin than exists anywhere today.
2. Against the product: the injectable relative should beat it and nobody has compared them. If the mechanism is real, Cortexin by injection — the only member of this family with measured brain penetration Kurkin 2021 — ought to outperform an oral extract of the same tissue on the same cognitive endpoint. Prediction: it does, by a margin large enough to make the tablet uninteresting. That head-to-head has never been run, and it is the comparison a vendor selling both has the least reason to fund.
3. An MMSE will not move in a healthy adult, and that is not a failure of the product. The explant work reports effects that are larger in tissue from OLD animals Ryzhak 2015 Khavinson 2002. A ceiling-bound screening instrument in a cognitively normal person has nowhere to go. If somebody's MMSE does move, look for sleep, alcohol or a concurrent change before crediting the tablet.
4. A glutamatergic profile predicts a glutamatergic side effect. AMPA and kainate binding at 80.1% and 73.5% Kurkin 2021 is the signature of a compound that raises excitatory tone. In anyone with a seizure history that is the prediction worth taking seriously, and it points the opposite way from the class's gentle-regulator framing. No seizure has been reported with this product — because no adverse event of any kind has been reported with it, which is a different statement.
What nobody has tested yet
Nobody has put a tablet through a mass spectrometer. One pack, one dissolution, tandem mass spectrometry, and the buyer would know the peptide profile and molecular-weight distribution of what they are swallowing. It is a routine analytical run. No vendor publishes it, no independent lab has published it, and until somebody does, ‘brain peptide extract’ is a description of a process rather than of a substance.
Nobody has looked in blood after a dose. The explant and neuron work gives target concentrations — 0.01-100 ng/ml and 2-40 µg/ml respectively Ryzhak 2015 Yazar 2023. A single post-dose blood draw analyzed for peptide content would say whether the product reaches either range or misses both by orders of magnitude. That is one volunteer and one afternoon, and it would settle the central question on this page.
Nobody has compared the tablet to the capsule to the injection. The same vendor sells brain preparations in all three presentations under three names. A three-arm comparison on any shared endpoint would be the first compositional or clinical distinction ever published between two products in this catalog, and zero such comparisons exist for any organ in the line.
Extrapolation, labeled as such. If the active principle is genuinely a short peptide rather than the intact complex, then three things should follow that nobody has tested: the effect should survive deliberate proteolytic digestion of the tablet before dosing; it should be reproducible with defined synthetic peptides, which the same school already sells; and it should show no dependence on the tissue of origin once the sequence is fixed. The third prediction is the dangerous one for the product line, because tissue specificity is what seventeen different organ names are selling.
Cerebramin — its own safety story, not its class's
Three things specific to an oral brain-tissue extract.
What zero adverse events means, and what it does not. There are no published adverse events for this product because there are no published studies of it — the search on 8 September 2026 returned nothing. No setting has ever existed in which an adverse event could have been recorded, so the empty column is a measurement of the literature and not of the tablet. That is the opposite of the position a licensed drug is in, and the distinction is the single most useful thing a page like this can teach.
Animal nervous tissue carries a sourcing question the synthetic peptides do not. Bovine central nervous system material is the specified-risk-material category in every transmissible spongiform encephalopathy control framework in the world, and that is the reason those frameworks exist. No vendor for this product publishes the source species, the source country, the age of the animals or the processing controls. That is not a claim that the product is contaminated; it is the observation that nobody has published the information a buyer would need to rule it out, and for this tissue specifically that gap is worth naming.
The excitatory profile is the mechanism-derived warning. The measured receptor panel for the closest relative is dominated by AMPA and kainate binding Kurkin 2021, and a compound that raises fast excitatory transmission is a poor fit for anyone with epilepsy, a history of seizure, or a concurrent drug that lowers seizure threshold. Predicted from the pharmacology, not observed in a person, and stated as a prediction because that is what it is.
Sources read for this page
- Khavinson VKh, Cherniak SI, D'iakonov MM. [Cytamines--preparations for maintaining high professional ability and longevity in servicemen]. Voenno-Meditsinskii Zhurnal 2001 [Russian] · PMID 11338817
- Emirova LR, Rozhkova EA, Paniushkin VV, Mirzoian RS, Seifulla NR. [The effects of cytamines and their combinations with ecdystene, apilak, vitamax, and essentiale on the work capability of athletes]. Eksperimental'naia i Klinicheskaia Farmakologiia 2004 [Russian] · PMID 15341074
- Ryzhak GA, Nekrasov PA, Kiselev OI, Khavinson VKh. Study of protein components of natural peptide regulators. Bulletin of Experimental Biology and Medicine 2003 · PMID 12717513
- Rozhkova EA, Ordzhonikidze ZG, Druzhinin AE, Seifulla NR, Paniushkin VV, Kuznetsov IuM. [Using carnosine and natural antioxidants for the prophylaxis of acute post-loading oxidative stress]. Eksperimental'naia i Klinicheskaia Farmakologiia 2007 [Russian] · PMID 18074807
- Kurkin DV. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLoS One 2021 · PMID 34260655
- Yazar U. Cortexin Ameliorates High Glucose-Induced Neuropathy in Cultured Rat Sensory Neurons. Neuroendocrinology 2023 · PMID 37080184
- Kurkin DV. Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental Delay. Biomedicines 2025 · PMID 40299434
- Khavinson VKh, Malinin VV, Chalisova NI, Grigor'ev EI. [Tissue-specific action of peptides in tissue culture of rats of various ages]. Advances in Gerontology 2002;9:95-100 [Russian] · PMID 12096446
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Tokaev ES. [Bioactive substance used for treatment and preventive maintenance of liver diseases]. Voprosy Pitaniia 2007 [Russian] · PMID 17802767
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
Cerebramin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Cerebramin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Cerebramin moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Cerebramin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Cerebramin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Cerebramin — frequently asked questions
What is Cerebramin?
Cerebramin (Brain cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A Khavinson-school polypeptide fraction extracted from animal brain and pressed into a 155mg tablet — the older CYTAMIN line, not the synthetic cytogens or the cytomax capsules the Vault already covers. The class claim is tissue-specific regulation of gene expression in the organ the extract came from. The only member of this family whose pharmacology has actually been measured is the injectable brain preparation Cortexin, which reached mouse brain at 6-8% of whole-blood concentration and screened as a glutamatergic agent — 80.1% binding at AMPA and 73.5% at kainate receptors — rather than as the DNA-binding regulator the class is sold as.
Where can I find Cerebramin dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Cerebramin protocol are available to members inside Skool. This public page covers what Cerebramin is, how it works and the evidence.
What is the half-life of Cerebramin?
Cerebramin has an approximate half-life of Not characterized — no analytical method for this preparation has been published, which is part of what determines how often it's dosed.
What's the evidence behind Cerebramin?
Current evidence level: No published study of this product. The literature belongs to the parenteral extracts and the synthetic peptides of the same school.. Cerebramin is offered for research purposes only and is not an approved medicine.
What Cerebramin is used for
Cerebramin appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.